Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

NCT07015671 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence Study in Healthy Subjects
PK/PD

Interventions

DRUG: 10 mg Torsemide tablet
DRUG: 25 mg Aldactone (Spironolactone) tablet
DRUG: FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet

Sponsor

Sarfez Pharmaceuticals, Inc.